You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Framework for mHealth App Security and Privacy Analysis

    SBC: UBITRIX INTERNATIONAL, INC.            Topic: NLM

    PROJECT SUMMARY/ABSTRACT With the increased use of mobile health (mHealth) apps to improve health outcomes, protecting private health data is becoming increasingly important. These mHealth apps are offered by healthcare providers and used by patients for various reasons such as paying bills, scheduling appointments, sending messages to providers, accessing lab results, and viewing prescriptions an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Programming Metabolically Fit TILs for Immunotherapy

    SBC: LIPO-IMMUNO TECH LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Development and Evaluation of Rosette Array Technology for HumanNeurodevelopmental Toxicity Screening

    SBC: Neurosetta LLC            Topic: R

    Project Summary Pre-clinical and pre-field toxicology testing of new drugs and chemicals does not routinely include direct assessment of human developmental neurotoxicity (DNT). Current standards for DNT testing require use of animal models with limited throughput and significant differences from human central nervous system (CNS) development. As such, many chemical products have required post-app ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Critical angle reflection imaging for label-free quantification of molecular interactions

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    TITLE: Critical angle reflection imaging (CARi) for label-free quantification of molecular interactions SUMMARYMeasuring molecular interactions of proteins are critical for understanding protein functions and cellular processes, for discovery and validating biomarkers, and for developing and screening drugs. In particular, membrane proteins play key roles in many cellular functions and are the lar ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Adjustable prosthetic sockets for children and adolescents with lower limb loss to accommodate growth

    SBC: IFIT PROSTHETICS, LLC            Topic: NICHD

    Pediatric limb loss, although relatively infrequent compared to adults, results in substantial hardship for children and their families. The principal business interest? iFIT Prosthetics, LLC®? successfully developed and manufactured innovative, fully adjustable, transtibial and transfemoral prosthetic devices, and demonstrated their safety, comfort, and functionality in adults. Made of injection ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Affordable sialoglycans and associated reagents for expanded chemoenzymatic production

    SBC: Integrated Micro-Chromatography Systems, Inc.            Topic: 300

    Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of peptide nucleic acid antibiotics

    SBC: NUBAD LLC            Topic: NIAID

    The world is rapidly heading towards a pre-1940’s scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as influenza, SARS, COVID-19, tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robu ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR) from a nuclear incident. The pathobiology of radiation pneumonitis and radiation-induced lung fibrosis (RILF) is complex but includes the deleterious effects of unchecked inflammation (reactive oxyg ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government